Selumetinib

Phase 1/2Terminated

0 views this week 0 watching💤 Quiet

Interest: 24/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

AIDS-related Kaposi's Sarcoma

Conditions

AIDS-related Kaposi's Sarcoma

Trial Timeline

Jun 15, 2012 → Dec 20, 2017

NCT ID

NCT01752569

About Selumetinib

Selumetinib is a phase 1/2 stage product being developed by AstraZeneca for AIDS-related Kaposi's Sarcoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT01752569. Target conditions include AIDS-related Kaposi's Sarcoma.

What happened to similar drugs?

0 of 1 similar drugs in AIDS-related Kaposi's Sarcoma were approved

Approved (0) Terminated (0) Active (1)

🔄Recombinant Human Papillomavirus Nonavalent VaccineMerckPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (10)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03259633	Pre-clinical	Completed	—	—	NF type1 With Inoperable Plexiform Neurofibromas
NCT04924608	Phase 3	Active	Nov 19, 2021	Feb 15, 2029	Neurofibromatosis 1
NCT05101148	Phase 1	Active	Jul 21, 2021	Apr 28, 2028	Neurofibromatosis Type 1
NCT04590235	Phase 1	Active	Dec 16, 2020	Aug 31, 2026	Neurofibromatosis 1
NCT04495127	Phase 1	Completed	Aug 31, 2020	Mar 24, 2023	Neurofibromatosis Type 1
NCT03326388	Phase 1/2	Completed	Sep 26, 2019	Feb 14, 2024	Neurofibromatosis Type 1
NCT03095248	Phase 2	Terminated	May 8, 2017	May 21, 2024	Neurofibromatosis 2
NCT02063204	Phase 1	Completed	Mar 1, 2014	Jul 1, 2014	Solid Tumours
NCT01960374	Phase 1	Completed	Oct 1, 2013	May 1, 2014	Healthy Volunteers Pharmacokinetic Study
NCT01752569	Phase 1/2	Terminated	Jun 15, 2012	Dec 20, 2017	AIDS-related Kaposi's Sarcoma

Competing Products

1 competing product in AIDS-related Kaposi's Sarcoma

See all competitors

Product	Company	Stage	Hype Score
Recombinant Human Papillomavirus Nonavalent Vaccine	Merck	Phase 3	40